Yu-Wei Chen discusses his research focusing on androgen receptor (AR) and neuroendocrine signatures in prostate cancer using the Caris database. This study classifies prostate tumors into four molecular subgroups, revealing significant insights into their distinct behaviors and treatment responses. Dr. Chen’s findings challenge the conventional histological classifications by demonstrating…
Zach Klaassen and Zach Reardon delve into the nuances of managing nonmetastatic castration-resistant prostate cancer (nmCRPC) in clinical practice. Dr. Reardon discusses the evolving landscape…
Ashish Kamat interviews Shilpa Gupta about the best of ASCO 2024 in advanced bladder cancer. Dr. Gupta discusses three abstracts: the CheckMate-901 trial’s analysis of…
Neeraj Agarwal interviews Marta Garcia de Herreros about presentation on tumor suppressor gene (TSG) signatures in metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Garcia de Herreros…
Duncan Gilbert discusses the PATCH trial, comparing transdermal estradiol with LHRH agonists for androgen suppression in non-metastatic prostate cancer. Dr. Gilbert discusses the trial design,…
Rashid Sayyid and Zachary Klaassen discuss the resurgence of radium-223 in treating metastatic castration-resistant prostate cancer (mCRPC), focusing on the PEACE-3 trial results. The conversation…
Ashley Ross and David Morris discuss the use of the Decipher Genomic Classifier in metastatic hormone-sensitive prostate cancer (mHSPC). They explore how Decipher can help…
Zach Klaassen engages with Talal El Zarif and Karl Semaan to discuss the results of the KEYNOTE-564 trial on adjuvant immunotherapy for renal cell carcinoma…
The biggest medical advances of 2024 will be remembered as significant long into the future.
Zach Klaassen interviews Neal Shore about the EMBARK trial’s post hoc analysis by age. The study examines the efficacy of enzalutamide alone or combined with…
Daniel Joyce discusses the financial impact of advanced prostate cancer treatments on patients. He presents research showing significant out-of-pocket costs for oral cancer therapies, particularly…
